Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCT01173874 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT01173874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01173874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2010
Completion date
November 30, 2013
Enrollment
120 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia